nach oben

HNO

Erschienen in:

12.11.2020 | Kopf-Hals-Tumoren | Leitthema

Spättoxizität nach primär konservativer Therapie

Dysphagie und Xerostomie

verfasst von: Prof. Dr. A. D. Jensen, C. Langer

Erschienen in: HNO | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Dysphagie und Xerostomie gehören weiterhin zu den wichtigsten Nebenwirkungen sowohl in der Akut- als auch in der Spätphase nach Strahlentherapie. Technische Entwicklungen der letzten beiden Dekaden haben zu einem besseren Nachweis dieser Nebenwirkungen und einem tieferen Verständnis der Ursachen beigetragen. Auf Basis dieser Erkenntnisse sowie von Verbesserungen in der Planungs- und Bestrahlungstechnik konnten radiogene Spätfolgen bereits durch den Einsatz der intensitätsmodulierten Strahlentherapie in Frequenz und Ausprägung deutlich reduziert werden, was mithin zu einer langfristig verbesserten Lebensqualität strahlentherapeutisch behandelter Patienten mit Kopf-Hals-Tumoren beitragen konnte. Weitere Verbesserungen verspricht man sich durch den Einsatz noch konformalerer Techniken wie der Therapie mit Protonen, die an verschiedenen Einrichtungen bereits prospektiv für den Einsatz in der Kopf-Hals-Onkologie untersucht wird.

Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362(9388):933–940 (Erratum in: Lancet. 2003; 362(9395):1588)PubMedCrossRef

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92–98PubMedCrossRef

Bourhis J, Sire C, Graff P et al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13:145–153PubMedCrossRef

Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G (2004) Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22(1):69–76PubMedCrossRef

Pignon JP, Bourhis J, Domenge C, Designé L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. meta-analysis of chemotherapy on head and neck cancer. Lancet 355(9208):949–955PubMedCrossRef

Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT (2014) Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 32(34):3858–3866PubMedPubMedCentralCrossRef

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852PubMedCrossRef

Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German cancer society 95-06 prospective randomized trial. J Clin Oncol 23(6):1125–1135PubMedCrossRef

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32(27):2940–2950PubMedPubMedCentralCrossRef

10.

Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J (2015) Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):208–220PubMedCrossRef

11.

Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D’Ambrosio C, Turner SJ, Pandeshwara JS, Bourhis J (2009) Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27(7):1100–1107PubMedCrossRef

12.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL, EORTC 24971/TAX 323 Study Grou (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704PubMedCrossRef

13.

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI, TAX 324 Study Group. (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715PubMedCrossRef

14.

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D’Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E, GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial. Ann Oncol 28(9):2206–2212PubMedCrossRef

15.

Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264PubMedCrossRef

16.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32(25):2735–2743PubMedPubMedCentralCrossRef

17.

Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W (2007) TAME: development of a new method for summarising adverse events of cancer treatment by the radiation therapy oncology group. Lancet Oncol 8(7):613–624PubMedCrossRef

18.

Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK (2012) Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307(7):693–703PubMedPubMedCentralCrossRef

19.

Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92(9):709–720PubMedCrossRef

20.

Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E, PARSPORT trial management group (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12(2):127–136PubMedPubMedCentralCrossRef

21.

Langendijk JA, Doornaert P, Verdonck-de Leeuw IM et al (2008) Impact of late treatment-related toxicity on quality of life. J Clin Oncol 26:3770–3776PubMedCrossRef

22.

Thomson WM, Chalmers JM, Spencer AJ, Williams SM (1999) The xerostomia inventory: a multi-item approach to measuring dry mouth. Community Dent Health 16(1):12–17PubMed

23.

Thomson WM, van der Putten GJ, de Baat C, Ikebe K, Matsuda K, Enoki K, Ling GY (2011) Shortening the xerostomia inventory. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112(3):322–327PubMedPubMedCentralCrossRef

24.

Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK (1993) The European organization for research and treatment of cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC study group on quality of life. Qual Life Res 2(4):287–295PubMedCrossRef

25.

Bjordal K, Kaasa S (1992) Psychometric validation of the EORTC core quality of life questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 31(3):311–321PubMedCrossRef

26.

Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ, Kaasa S (1994) Development of a European organization for research and treatment of cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC quality of life study group. Acta Oncol 33(8):879–885PubMedCrossRef

27.

Singer S, Araújo C, Arraras JI, Baumann I, Boehm A, Brokstad Herlofson B, Castro Silva J, Chie WC, Fisher S, Guntinas-Lichius O, Hammerlid E, Irarrázaval ME, Jensen Hjermstad M, Jensen K, Kiyota N, Licitra L, Nicolatou-Galitis O, Pinto M, Santos M, Schmalz C, Sherman AC, Tomaszewska IM, Verdonck de Leeuw I, Yarom N, Zotti P, Hofmeister D, EORTC Quality of Life and the EORTC Head and Neck Cancer Groups (2015) Measuring quality of life in patients with head and neck cancer: update of the EORTC QLQ-H&N module, phase III. Head Neck 37:1358–1367PubMedCrossRef

28.

Singer S, Amdal CD, Hammerlid E, Tomaszewska IM, Castro Silva J, Mehanna H, Santos M, Inhestern J, Brannan C, Yarom N, Fullerton A, Pinto M, Arraras JI, Kiyota N, Bonomo P, Sherman AC, Baumann I, Galalae R, Fernandez Gonzalez L, Nicolatou-Galitis O, Abdel-Hafeez Z, Raber-Durlacher J, Schmalz C, Zotti P, Boehm A, Hofmeister D, Krejovic Trivic S, Loo S, Chie WC, Bjordal K, Brokstad Herlofson B, Grégoire V, Licitra L, EORTC Quality of Life and the EORTC Head and Neck Cancer Groups (2019) International validation of the revised European organisation for research and treatment of cancer head and neck cancer module, the EORTC QLQ-HN43: phase IV. Head Neck 41(6):1725–1737PubMedCrossRef

29.

Navazesh M, Kumar SK, University of Southern California School of Dentistry (2008) Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 139:35S–40SPubMedCrossRef

30.

Bohuslavizki KH, Brenner W, Lassmann S, Tinnemeyer S, Kalina S, Clausen M, Henze E (1997) Quantitative salivary gland scintigraphy—a recommended examination prior to and after radioiodine therapy. Nuklearmedizin 36(3):103–109PubMedCrossRef

31.

Münter MW, Karger CP, Hoffner SG, Hof H, Thilmann C, Rudat V, Nill S, Wannenmacher M, Debus J (2004) Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 58(1):175–184PubMedCrossRef

32.

Münter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, Huber P, Debus J, Karger CP (2007) Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. Int J Radiat Oncol Biol Phys 67(3):651–659PubMedCrossRef

33.

Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA (2009) Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 73(2):410–415PubMedCrossRef

34.

Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589PubMedPubMedCentralCrossRef

35.

Rütten H, Pop LA, Janssens GO, Takes RP, Knuijt S, Rooijakkers AF, van den Berg M, Merkx MA, van Herpen CM, Kaanders JH (2011) Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic. Int J Radiat Oncol Biol Phys 81(4):923–929PubMedCrossRef

36.

Russi EG, Corvò R, Merlotti A, Alterio D, Franco P, Pergolizzi S, De Sanctis V, Ruo Redda MG, Ricardi U, Paiar F, Bonomo P, Merlano MC, Zurlo V, Chiesa F, Sanguineti G, Bernier J (2012) Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian association of radiation oncology. Cancer Treat Rev 38(8):1033–1049PubMedCrossRef

37.

Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ, Karlsson U, Nguyen LM, Rose S, Dutta S, Sallah S (2006) Evolution of chronic dysphagia following treatment for head and neck cancer. Oral Oncol 42(4):374–380PubMedCrossRef

38.

Hutcheson KA, Lewin JS, Barringer DA, Lisec A, Gunn GB, Moore MW, Holsinger FC (2012) Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer 118(23):5793–5799PubMedCrossRef

39.

Caudell JJ, Carroll WR, Spencer SA, Bonner JA (2011) Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx. Cancer 117(19):4447–4451PubMedCrossRef

40.

Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM (2008) Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 72(4):1110–1118PubMedCrossRef

41.

Nguyen NP, Smith HJ, Dutta S, Alfieri A, North D, Nguyen PD, Lee H, Martinez T, Lemanski C, Ludin A, Nguyen LM, Sallah S (2007) Aspiration occurence during chemoradiation for head and neck cancer. Anticancer Res 27(3B):1669–1672PubMed

42.

van der Laan HP, Bijl HP, Steenbakkers RJ, van der Schaaf A, Chouvalova O, Vemer-van den Hoek JG, Gawryszuk A, van der Laan BF, Oosting SF, Roodenburg JL, Wopken K, Langendijk JA (2015) Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia. Radiother Oncol 115(1):56–62PubMedCrossRef

43.

Eisbruch A, Lyden T, Bradford CR, Dawson LA, Haxer MJ, Miller AE, Teknos TN, Chepeha DB, Hogikyan ND, Terrell JE, Wolf GT (2002) Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 53(1):23–28PubMedCrossRef

44.

Eisbruch A, Schwartz M, Rasch C et al (2004) Dysphagia and aspiration after chemoradiotherapy for head and neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 60:1425–1439PubMedCrossRef

45.

Eisbruch A, Levendag PC, Feng FY, Teguh D, Lyden T, Schmitz PI, Haxer M, Noever I, Chepeha DB, Heijmen BJ (2007) Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys 69(2):S40–2PubMedPubMedCentralCrossRef

46.

Kaae JK, Johnsen L, Hansen CR, Kristensen MH, Brink C, Eriksen JG (2019) Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. Acta Oncol 58(10):1366–1372PubMedCrossRef

47.

Chen AM, Li B‑Q, Lau DH et al (2010) Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 78:1026–1032PubMedCrossRef

48.

Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, Goepfert H (2001) The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 127(7):870–876PubMed

49.

Kraus EM, Rommel N, Stoll LH, Oettinger A, Vogel AP, Synofzik M (2018) Validation and psychometric properties of the German version of the SWAL-QOL. Dysphagia 33(4):431–440PubMedCrossRef

50.

List MA, Ritter-Sterr CA, Baker TM, Colangelo LA, Matz G, Pauloski BR, Logemann JA (1996) Longitudinal assessment of quality of life in laryngeal cancer patients. Head Neck 18(1):1–10PubMedCrossRef

51.

Silbergleit AK, Schultz L, Jacobson BH, Beardsley T, Johnson AF (2011) The dysphagia handicap index: development and validation. Dysphagia 27(1):46–52PubMedCrossRef

52.

Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH (1995) RTOG late effects working group. Overview. Late effects of normal tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31(5):1041–1042PubMedCrossRef

53.

Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, Gonzales-Gonzales D, Horiot JC, Bolla M, Bartelink H (1995) EORTC late effects working group. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31(5):1043–1047PubMedCrossRef

54.

National Cancer Institute (2020) CTEP cancer therapy evaluation program. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Zugegriffen: 12. Mai 2020

55.

Langmore SE, Schatz K, Olsen N (1988) Fiberoptic endoscopic examination of swallowing safety: a new procedure. Dysphagia 2(4):216–219PubMedCrossRef

56.

Langius J, van Dijk A, Doornaert P et al (2013) More than 10 % weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer 65:76–83PubMedCrossRef

57.

Koyfman SA, Adelstein DJ (2012) Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. Int J Radiat Oncol Biol Phys 84:581–589PubMedCrossRef

58.

Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P (2001) Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 91(9):1785–1790PubMedCrossRef

59.

Corry J, Poon W, McPhee N et al (2009) Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. Head Neck 31:867–876PubMedCrossRef

60.

Corry J, Poon W, McPhee N et al (2008) Randomized study of percutaneous endoscopic gastroscopy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation. J Med Imaging Radiat Oncol 52:503–510PubMedCrossRef

61.

Assenat E, Thezenas S, Flori N et al (2011) Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy. J Pain Symptom Manage 42:548–556PubMedCrossRef

62.

Baschnagel AM, Yadav S, Marina O et al (2014) Toxicities and costs of placing prophylactic and reactive percutaneous gastrostomy tubes in patients with locally advanced head and neck cancers treated with chemoradiotherapy. Head Neck 36:1155–1161PubMedCrossRef

63.

Madhoun MF (2011) Prophylactic PEG placement in head and neck cancer: How many feeding tubes are unused (and unnecessary)? World J Gastroenterol 17:1004PubMedPubMedCentralCrossRef

64.

Silander E, Nyman J, Bove M, Johansson L, Larsson S, Hammerlid E (2012) Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer—a randomized study. Head Neck 34:1–9PubMedCrossRef

65.

Brahme A, Roos JE, Lax I (1982) Solution of an integral equation encountered in rotation therapy. Phys Med Biol 27(10):1221–1229PubMedCrossRef

66.

Brahme A (1982) Physical and biologic aspects on the optimum choice of radiation modality. Acta Radiol Oncol 21(6):469–479PubMedCrossRef

67.

Ling CC, Burman C, Chui CS, Kutcher GJ, Leibel SA, LoSasso T, Mohan R, Bortfeld T, Reinstein L, Spirou S, Wang XH, Wu Q, Zelefsky M, Fuks Z (1996) Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 35(4):721–730PubMedCrossRef

68.

Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50(3):695–704PubMedCrossRef

69.

Blanco AI, Chao KS, El Naqa I, Franklin GE, Zakarian K, Vicic M, Deasy JO (2005) Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys 62(4):1055–1069PubMedCrossRef

70.

Li Y, Taylor JM, Ten Haken RK, Eisbruch A (2007) The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 67(3):660–669PubMedCrossRef

71.

Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74(1):1–8PubMedCrossRef

72.

Murdoch-Kinch CA, Kim HM, Vineberg KA, Ship JA, Eisbruch A (2008) Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 72(2):373–382PubMedPubMedCentralCrossRef

73.

Daly ME, Lieskovsky Y, Pawlicki T, Yau J, Pinto H, Kaplan M, Fee WE, Koong A, Goffinet DR, Xing L, Le QT (2007) Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 29(3):211–220PubMedCrossRef

74.

Murata Y, Zhang L, Ishida R, Aung W, Taura S, Hossain M, Yoshimura R, Hoshina M, Akaike H, Sugaya T, Shibuya H (2002) Maintained salivary function after brachytherapy in patients with head and neck carcinomas—evaluation using quantitative salivary gland scintigraphy. Acta Oncol 41(7–8):684–688PubMedCrossRef

75.

Moiseenko V, Wu J, Hovan A, Saleh Z, Apte A, Deasy JO, Harrow S, Rabuka C, Muggli A, Thompson A (2012) Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset. Int J Radiat Oncol Biol Phys 82(3):1108–1114PubMedCrossRef

76.

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED (2010) Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76(3):S3–9PubMedPubMedCentralCrossRef

77.

Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A (2010) Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 76(3):S58–63PubMedPubMedCentralCrossRef

78.

Lee TF, Fang FM (2013) Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. Radiother Oncol 106(3):352–358PubMedCrossRef

79.

Beetz I, Schilstra C, van der Schaaf A, van den Heuvel ER, Doornaert P, van Luijk P, Vissink A, van der Laan BF, Leemans CR, Bijl HP, Christianen ME, Steenbakkers RJ, Langendijk JA (2012) NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother Oncol 105(1):101–106PubMedCrossRef

80.

Beetz I, Steenbakkers RJ, Chouvalova O, Leemans CR, Doornaert P, van der Laan BF, Christianen ME, Vissink A, Bijl HP, van Luijk P, Langendijk JA (2014) The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia. Acta Oncol 53(5):597–604PubMedCrossRef

81.

Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA (2003) Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55(2):312–321PubMedCrossRef

82.

Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT (2005) Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma—the University of Iowa experience. Int J Radiat Oncol Biol Phys 63(2):410–421PubMedCrossRef

83.

Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ (2006) Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64(1):57–62PubMedCrossRef

84.

Schoenfeld GO, Amdur RJ, Morris CG, Li JG, Hinerman RW, Mendenhall WM (2008) Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 71(2):377–385PubMedCrossRef

85.

Cannon DM, Lee NY (2008) Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 70(3):660–665PubMedCrossRef

86.

Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, Murthy V, Budrukkar A, Dinshaw K, Prabhash K, Chaturvedi P, D’Cruz A (2012) Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol 104(3):343–348PubMedCrossRef

87.

Ghosh-Laskar S, Yathiraj PH, Dutta D, Rangarajan V, Purandare N, Guta T et al (2016) Prospective randomized controlled trial to compare 3‑dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: long-term results. Head Neck 38(1):E1481–1487PubMedCrossRef

88.

Bourhis J, Auperin A, Alfonsi M, Shan X, Rives M, Pointreau Y et al (2017) Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: results of the GORTEC 2004-01 randomized trial. J Clin Oncol 35(15):6015CrossRef

89.

Braam PM, Roesink JM, Raaijmakers CP, Busschers WB, Terhaard CH (2007) Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiat Oncol 2:3PubMedPubMedCentralCrossRef

90.

Braam PM, Terhaard CH, Roesink JM, Raaijmakers CP (2006) Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 66(4):975–980PubMedCrossRef

91.

Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A (2003) Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 57(1):61–70PubMedCrossRef

92.

Parliament MB, Scrimger RA, Anderson SG, Kurien EC, Thompson HK, Field GC, Hanson J (2004) Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 58(3):663–673PubMedCrossRef

93.

Beetz I, Schilstra C, Visink A, van der Schaaf A, Bijl HP, van der Laan BF, Steenbakkers RJ, Langendijk JA (2013) Role of minor salivary glands in developing patient-rated xerostomia and sticky saliva during day and night. Radiother Oncol 109(2):311–316PubMedCrossRef

94.

Beetz I, Schilstra C, van Luijk P, Christianen ME, Doornaert P, Bijl HP, Chouvalova O, van den Heuvel ER, Steenbakkers RJ, Langendijk JA (2012) External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiother Oncol 105(1):94–100PubMedCrossRef

95.

Seikaly H, Jha N, Harris JR, Barnaby P, Liu R, Williams D, McGaw T, Rieger J, Wolfaardt J, Hanson J (2004) Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg 130(8):956–961PubMedCrossRef

96.

Seikaly H, Jha N, McGaw T, Coulter L, Liu R, Oldring D (2001) Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 111(2):347–352PubMedCrossRef

97.

Rudat V, Münter M, Rades D, Grötz KA, Bajrovic A, Haberkorn U, Brenner W, Debus J (2008) The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol 89(1):71–80PubMedCrossRef

98.

Konings AW, Cotteleer F, Faber H, van Luijk P, Meertens H, Coppes RP (2005) Volume effects and region-dependent radiosensitivity of the parotid gland. Int J Radiat Oncol Biol Phys 62(4):1090–1095PubMedCrossRef

99.

Steenbakkers R, Stokman M, Kierkels R, Schuurman M, Van den Hoek A, Bijl H, Dieters M, Coppes R, Langendijk J, Vanluijk P (2019) OC-0631 stem cell sparing IMRT for head and neck cancer patients: a double-blind randomized controlled trial. Radiother Oncol 133:S335–S336CrossRef

100.

101.

Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D (2009) Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 38(4):522–532PubMedCrossRef

102.

Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A (2010) Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 28(16):2732–2738PubMedPubMedCentralCrossRef

103.

Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68(5):1289–1298PubMedCrossRef

104.

Christianen ME, Verdonck-de Leeuw IM, Doornaert P, Chouvalova O, Steenbakkers RJ, Koken PW, Leemans CR, Oosting SF, Roodenburg JL, van der Laan BF, Slotman BJ, Bijl HP, Langendijk JA (2015) Patterns of long-term swallowing dysfunction after definitive radiotherapy or chemoradiation. Radiother Oncol 117(1):139–144PubMedCrossRef

105.

Christianen ME, Schilstra C, Beetz I, Muijs CT, Chouvalova O, Burlage FR, Doornaert P, Koken PW, Leemans CR, Rinkel RN, de Bruijn MJ, de Bock GH, Roodenburg JL, van der Laan BF, Slotman BJ, Verdonck-de Leeuw IM, Bijl HP, Langendijk JA (2012) Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. Radiother Oncol 105(1):107–114PubMedCrossRef

106.

Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75(2):385–392PubMedCrossRef

107.

Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, Andersen LJ, Andersen E, Grau C (2012) Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol 103(1):69–75PubMedCrossRef

108.

Mortensen HR, Jensen K, Aksglæde K, Behrens M, Grau C (2013) Late dysphagia after IMRT for head and neck cancer and correlation with dose-volume parameters. Radiother Oncol 107(3):288–294PubMedCrossRef

109.

Caudell JJ, Meredith RF, Spencer SA, Keene KS, Dobelbower MC, Bonner JA (2010) Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer. Int J Radiat Oncol Biol Phys 76(1):164–168PubMedCrossRef

110.

Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA (2010) Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 76(2):403–409PubMedCrossRef

111.

Machtay M, Moughan J, Farach A, Martin-O’Meara E, Galvin J, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2012) Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. Int J Radiat Oncol Biol Phys 84(4):983–989PubMedPubMedCentralCrossRef

112.

Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ, Kolkman-Deurloo IK, Prevost JB, Poll J, Schmitz PI, Heijmen BJ (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85(1):64–73PubMedCrossRef

113.

Wopken K, Bijl HP, van der Schaaf A, van der Laan HP, Chouvalova O, Steenbakkers RJ, Doornaert P, Slotman BJ, Oosting SF, Christianen ME, van der Laan BF, Roodenburg JL, Leemans CR, Verdonck-de Leeuw IM, Langendijk JA (2014) Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer. Radiother Oncol 113(1):95–101PubMedCrossRef

114.

van der Laan HP, Christianen ME, Bijl HP, Schilstra C, Langendijk JA (2012) The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: an in silico planning comparative study. Radiother Oncol 103(1):76–81PubMedCrossRef

115.

van der Laan HP, Gawryszuk A, Christianen ME, Steenbakkers RJ, Korevaar EW, Chouvalova O, Wopken K, Bijl HP, Langendijk JA (2013) Swallowing-sparing intensity-modulated radiotherapy for head and neck cancer patients: treatment planning optimization and clinical introduction. Radiother Oncol 107(3):282–287PubMedCrossRef

116.

Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA (2015) CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines. Radiother Oncol 117(1):83–90PubMedCrossRef

117.

Kierkels RGJ, Wopken K, Visser R, Korevaar EW, van der Schaaf A, Bijl HP, Langendijk JA (2016) Multivariable normal tissue complication probability model-based treatment plan optimization for grade 2–4 dysphagia and tube feeding dependence in head and neck radiotherapy. Radiother Oncol 121(3):374–380PubMedCrossRef

118.

Kanayama N, Kierkels RGJ, van der Schaaf A, Steenbakkers RJHM, Yoshioka Y, Nishiyama K, Fujii T, Ogawa K, Langendijk JA, Teshima T (2018) External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6 months after definitive radiotherapy for head and neck cancer. Radiother Oncol 129(2):403–408PubMedCrossRef

119.

Kierkels RG, Korevaar EW, Steenbakkers RJ, Janssen T, van’t Veld AA, Langendijk JA, Schilstra C, van der Schaaf A (2014) Direct use of multivariable normal tissue complication probability models in treatment plan optimisation for individualised head and neck cancer radiotherapy produces clinically acceptable treatment plans. Radiother Oncol 112(3):430–436PubMedCrossRef

120.

McKenna WG, Lenkinski RE, Hendrix RA, Vogele KE, Bloch P (1989) The use of magnetic resonance imaging and spectroscopy in the assessment of patients with head and neck and other superficial human malignancies. Cancer 64(10):2069–2075PubMedCrossRef

121.

Samołyk-Kogaczewska N, Sierko E, Zuzda K, Gugnacki P, Szumowski P, Mojsak M, Burzyńska-Śliwowska J, Wojtukiewicz MZ, Szczecina K, Jurgilewicz DH (2019) PET/MRI- guided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. Strahlenther Onkol 195(9):780–791PubMedPubMedCentralCrossRef

122.

Leclerc M, Lartigau E, Lacornerie T, Daisne JF, Kramar A, Grégoire V (2015) Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy. Radiother Oncol 116(1):87–93PubMedCrossRef

123.

Delouya G, Igidbashian L, Houle A, Bélair M, Boucher L, Cohade C, Beaulieu S, Filion EJ, Coulombe G, Hinse M, Martel C, Després P, Nguyen-Tan PF (2011) ¹⁸F‑FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer. Radiother Oncol 101(3):362–368PubMedCrossRef

124.

Moule RN, Kayani I, Moinuddin SA, Meer K, Lemon C, Goodchild K, Saunders MI (2010) The potential advantages of (18)FDG PET/CT-based target volume delineation in radiotherapy planning of head and neck cancer. Radiother Oncol 97(2):189–193PubMedCrossRef

125.

Henriques de Figueiredo B, Barret O, Demeaux H, Lagarde P, De-Mones-Del-Pujol E, Kantor G, de Clermont-Gallerande H, Richaud P, Fernandez P (2009) Comparison between CT- and FDG-PET-defined target volumes for radiotherapy planning in head-and-neck cancers. Radiother Oncol 93(3):479–482PubMedCrossRef

126.

Gardner M, Halimi P, Valinta D, Plantet MM, Alberini JL, Wartski M, Banal A, Hans S, Floiras JL, Housset M, Labib A (2009) Use of single MRI and 18F-FDG PET-CT scans in both diagnosis and radiotherapy treatment planning in patients with head and neck cancer: advantage on target volume and critical organ delineation. Head Neck 31(4):461–467PubMedCrossRef

127.

Grégoire V, Coche E, Cosnard G, Hamoir M, Reychler H (2000) Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 56(2):135–150PubMedCrossRef

128.

Levendag P, Braaksma M, Coche E, van Der Est H, Hamoir M, Muller K, Noever I, Nowak P, van Sörensen De Koste J, Grégoire V (2004) Rotterdam and brussels CT-based neck nodal delineation compared with the surgical levels as defined by the American academy of otolaryngology-head and neck surgery. Int J Radiat Oncol Biol Phys 58(1):113–123PubMedCrossRef

129.

Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H (2003) CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol 69(3):227–236PubMedCrossRef

130.

Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Lengele B (2014) Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 110(1):172–181PubMedCrossRef

131.

Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, Lee A, Maingon P, Mäkitie A, Micciche’ F, Nicolai P, O’Sullivan B, Poitevin A, Porceddu S, Składowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C (2018) Delineation of the primary tumour clinical target volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: aIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol 126(1):3–24PubMedCrossRef

132.

Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, Kazmierska J, Langendijk JA, Ozsahin M, O’Sullivan B, Bourhis J, Grégoire V (2019) Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiother Oncol 134:1–9PubMedCrossRef

133.

Nutting CM, Rooney K, Foran B, Pettit L, Beasley M, Finneran L, Roe J, Tyler J, Roques T, Cook A, Petkar I, Bhide S, Srinvasan D, Boon C, de Winton E, Frogley R, Mertens K, Emson M, Hall E (2020) Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer. J Clin Oncol 38(15):6508–6508CrossRef

134.

Contreras JA, Spencer C, DeWees T, Haughey B, Henke LE, Chin RI, Paniello R, Rich J, Jackson R, Oppelt P, Pipkorn P, Zevallos J, Chernock R, Nussenbaum B, Daly M, Gay H, Adkins D, Thorstad W (2019) Eliminating postoperative radiation to the pathologically node-negative neck: long-term results of a prospective phase II study. J Clin Oncol 37(28):2548–2555PubMedCrossRef

135.

Langendijk JA, Boersma LJ, Rasch CRN, van Vulpen M, Reitsma JB, van der Schaaf A, Schuit E (2018) Clinical trial strategies to compare protons with photons. Semin Radiat Oncol 28(2):79–87PubMedCrossRef

136.

Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M (2013) Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 107:267–273PubMedCrossRef

137.

Frank SJ et al (2013) Randomized trial of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck. https://clinicaltrials.gov/ct2/show/NCT01893307. Zugegriffen: 12. Mai 2020

138.

Grau C et al DAHANCA database. https://clinicaltrials.gov/ct2/show/NCT04607694. Zugegriffen: 3. Nov. 2020

Titel: Spättoxizität nach primär konservativer Therapie
Dysphagie und Xerostomie
verfasst von: Prof. Dr. A. D. Jensen
C. Langer
Publikationsdatum: 12.11.2020
Verlag: Springer Medizin
Schlagwörter: Kopf-Hals-Tumoren
Strahlentherapie
Dysphagie
Dysphagie
Dysphagie
Erschienen in: HNO / Ausgabe 4/2021
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-020-00961-7

Weitere Lesetipps

Weißer Hautkrebs verursacht mehr Tote als das Melanom

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

Diagnose und Differenzierung von kutanen Zysten mit optischer Kohärenztomographie: eine Fallserie

Systemtherapie des Prostatakarzinoms im hohen Alter

CME: Januskinaseinhibitoren – Indikationen, Wirkung, Einsatz

Neue Konzepte beim Handekzem

Passend zum Thema

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1].

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1].

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bildnachweise

Medbee Screenshot/© Medbee | Springer Medizin, Narbe/© wutwhanfoto | iStock, Prof. Nast/© Bayer Vital GmbH, Dr. Tischler/© Bayer Vital GmbH, Basalzellkarzinom im Gesicht eines älteren Mannes/© flik47 | iStock, Prof. John/© Bayer Vital GmbH, Illustration der Definition der anatomischen Landmarken nach Baeet al. auf einer seitlichen Ansicht der Wange einer Frau/© D. Heimes, P. W. Kämmerer | wissen kompakt (18)·1:28-32, Psoriasis bei einem 7-Jährigen/© K. Süßmuthet al. / all rights reserved Springer Medizin Verlag GmbH, Dermatoskopische Untersuchung/© Taras Grebinets / stock.adobe.com (Symbolbild mit Fotomodell), Nahaufnahme einer Wunde/© RusN / Getty Images / iStock, Arbeiter pustet Maschinenstaub und Dreck von Werkzeug/© dragana991 / Getty Images / iStock (Symbolbild mit Fotomodell), Mukoide Pseudozyste am DII des linken Fußes./© S. Hobelsberger et al. doi.org/10.1007/s00105-023-05274-8 unter CC-BY 4.0, Frau mit Kopftuch und Infusion/© FatCamera / Getty Images / iStock (Symbolbild mit Fotomodell), Bakterienkultur in Petrischale/© nuengneng / Stock.adobe.com (Symbolbild mit Fotomodell), Basalzellkarzinome an der Nase/© Springer Medizin, Brustbestrahlung/© Lange T et al. / all rights reserved Springer Medizin Verlag GmbH, T-Zell-vermitteltes Pseudolymphom im Bereich einer rötlich-violetten Tätowierun/© Schubert, S., Duplexsonografische Befunde der Carotiden und der Vertebralarterien/© W. Freund, Hände mit Creme/© PeopleImages / iStock, Limbale Keratoconjunctivitis vernalis/© Messmer M. E. et al. / all rights reserved Springer Medizin Verlag GmbH, Hautbefund Ekzem auf Arm /© J. Szebényi et al. https://doi.org/10.1007/s00105-023-05122-9 unter CC-BY 4.0, Dermatophytose und Tinea unguium durch Trichophyton rubrum/© P. Nenoff et al. / all rights reserved Springer Medizin Verlag GmbH, Eine Frau mit strahlender Haut/© Jacob Lund / stock.adobe.com (Symbolbild mit Fotomodell), Dermatologin verödet Talgdrüsen bei Aknepatient/© K. Friedl (mit Einverständnis der abgebildeten Person), Liposuktion/© Garcia O. Springer Nature Switzerland AG 2020, Endonasaler Befund einer nasopharyngealen Raumforderung/© Springer Medizin Verlag GmbH, Hepatozelluläres Karzinom im Lebersegment VIII/© Wengert, G. et al. / all rights reserved Springer Medizin Verlag GmbH, Radiochirurgie: Hirnmetastase eines nichtkleinzelligen Lungenkarzinoms frontal rechts/© Diehl, C., Combs, S.E. / all rights reserved Springer Medizin Verlag GmbH, Ältere Frau mit Tabletten in der Hand/© LIGHTFIELD STUDIOS / stock.adobe.com (Symbolbild mit Fotomodell), Ventrales oberes Bodylift der männlichen Brust/© Promny T et al. / all rights reserved Springer Medizin Verlag GmbH, Eine Person kratzt sich am Arm/© DimaBerlin (Symbolbild mit Fotomodell), Heparin zur Antikoagulation/© Angel Arredondo / stock.adobe.com, Eine Mutter trägt eine Salbe auf ein Erythem bei ihrem Kind auf/© triocean / Getty Images / iStock (Symbolbild mit Fotomodellen), Nach Schlaganfall wird schreiben geübt/© Michaela Illian, Postradiogene Morphea/© Stephan R. Künzel und Claudia Günther / all rights reserved Springer Medizin Verlag GmbH, Checkpointhemmer/© molekuul.be / stock.adobe.com, Neurokranium vor und nach Resektion eines Glioblastoms/© Rieger, D. et al. doi.org/10.1007/s00761-024-01473-7 unter CC-BY 4.0, Infusion/© pix4U / Stock.adobe.com (Symbolbild mit Fotomodell), Generalisierter Pruritus bei Schwangeren/© LMU Klinikum München, Frauenklinik, Arzt und älterer Patient im Gespräch/© monkeybusinessimages / Getty Images / iStock (Symbolbild mit Fotomodellen), Vorderabschnittsfoto des rechten Auges/© Klemens P K et al. / all rights reserved Springer Medizin Verlag GmbH, Zervixkarzinom FIGO IB1/© Stübs, F.A., Beckmann, M.W. & Fehm, T. / all rights reserved Springer Medizin Verlag GmbH, Frau bei Augenuntersuchung/© Svitlana / Stock.adobe.com (Symbolbild mit Fotomodell), Ärztin am Bett einer Krebspatientin mit Infusion/© tonefotografia / stock.adobe.com (Symbolbild mit Fotomodellen), Medizinisches Personal redet mit einer Person im Untersuchungsraum/© Gorodenkoff / stock.adobe.com (Symbolbild mit Fotomodellen), Melasma im Gesichtsbereich einer Frau/© Springer Medizin, Anorektales Melanom im Bereich der Linea dentata mit schwärzlich-bräunlicher Pigmentierung/© J. Matull et al. / all rights reserved Springer Medizin Verlag GmbH, Erste-Hilfe-Koffer/© New Africa / Stock.adobe.com (Symbolbild mit Fotomodell), Pflanzen in Petrischalen/© Tatiana / stock.adobe.com (Symbolbild), HIFU (hochintensiver mikrofokussierter Ultraschall)-Behandlung/© C. Salavastru et al. / all rights reserved Springer Medizin Verlag GmbH, Ärztin schaut auf ihren Terminkalender/© Andrey Popov / stock.adobe.com (Symbolbild mit Fotomodell), Frauen mit verschiedenen Hauttypen/© N F / peopleimages.com / Stock.adobe.com (Symbolbild mit Fotomodellen), Bestrahlungsplan bei Rektumkarzinom/© Springer Medizin Verlag GmbH, Narbe/© askthegeek / Fotolia, Frau verabreicht sich Injektion/© Inna / stock.adobe.com (Symbolbild mit Fotomodell), Ein junger Arzt hält Tablet in der Hand/© NINENII / stock.adobe.com (Symbolbild mit Fotomodell), Kopf einer Person wird bestrahlt/© Mark Kostich | iStockphoto, Frau kratzt Hand mit Handekzem/© Irina Esau | Getty Images/iStockphoto, Titelbild CH Bepanthen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

CME: Kindliches obstruktives Schlafapnoesyndrom

Zellfreie Tumor-DNA in der molekularen Diagnostik bei Kopf-Hals-Karzinomen

Abstriche auf SARS-CoV-2 bei Tracheostomaträgern

Es braucht nur einen Blick zur Diagnose von Dyspnoe und Stridor

Oropharynxkarzinome: die Renaissance der Chirurgie?

Sichere R0-Resektion zur Vermeidung der adjuvanten Therapieeskalation beim Oropharynxkarzinom

Weitere Lesetipps

Passend zum Thema